Investors & Media

News

  • Item Type:
  • Year:
  • 7 Apr. 2021

    Kamada Announces Amendment to GLASSIA® License Agreement with Takeda

    Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021. Kamada to Receive from Takeda a Payment of $2 Million for the BLA Transfer. Final Sales-Based Milestone Payment of $5 Million Due to Kamada under the License […]

  • 31 Mar. 2021

    Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)

    As Previously Reported, 11 of the 12 Patients Recovered and were Discharged from Hospital; Seven Patients were Discharged at or Before Day 5 and the Remaining Four Patients were Discharged by Day 9 of Treatment. No Infusion-Related Reactions or Adverse Events Considered Related to Study Drug were Observed. Company Continues to Supply its IgG Product […]

  • 9 Mar. 2021

    Kamada to Present at the Jefferies Global Plasma Summit

    REHOVOT, Israel – March 9, 2021 – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies Virtual Global Plasma Summit, being held on March 11, 2021. Mr. London is scheduled to present at 9:35 a.m. Eastern Time. […]

  • 24 Feb. 2021

    Kamada Files Annual Report for the Year Ended December 31, 2020

    Rehovot, Israel, February 24, 2021 – Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commission (the “SEC”). The annual report, including the Company’s audited consolidated financial statements, […]

  • 10 Feb. 2021

    Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities

    Full-Year 2020 Revenues were $133.2 Million, In-Line with the Company’s Guidance; Adjusted EBITDA for 2020 was $25.1 Million Kamada EntersS. Plasma Collection Market Through Acquisition of an FDA-Approved Facility, Furthering its Strategic Goal of Becoming a Fully Integrated Specialty Plasma Company Focused on Growing its Hyperimmune IgG Portfolio Israeli Ministry of Health (IMOH) Initiated Treatment […]

  • 3 Feb. 2021

    Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021

    Rehovot, Israel, February 3, 2021 – Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2020, prior to the open of the U.S. financial markets on Wednesday, February 10, 2021. Kamada management will host an investment community […]

  • 1 Feb. 2021

    Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA

    Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA Transaction Represents Kamada’s Entry into U.S. Plasma Collection Market and Advances the Company’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Blood and Plasma Research, Inc. Primarily Focuses on Collecting Hyper-Immune Plasma, and Kamada Plans to Significantly […]

  • 13 Jan. 2021

    Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel

    The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024 Potential Collective Maximum Sales of the Three Products in the Israeli Market is Estimated at $5-$7 Million Annually These Sales Are in Addition to the Potential $20-$30 Million from the Recently Licensed Alvotech Biosimilar Portfolio  REHOVOT, […]

  • 5 Jan. 2021

    Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition

    Rehovot, Israel, January 5, 2021 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it has been selected as one of 10 winners of the Genesis Prize Foundation (GPF) Start-Up Nation Central (SNC) competition recognizing Israeli companies working to combat coronavirus and the damage of future pandemics. Based on its development […]

  • 21 Dec. 2020

    Kamada Added to the NASDAQ Biotechnology Index

    REHOVOT, Israel – December 21, 2020 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology […]